04:57 PM EST, 01/08/2025 (MT Newswires) -- Scholar Rock ( SRRK ) said Wednesday it aims to submit a biologics license application in the US and a marketing authorization application in Europe for apitegromab to treat spinal muscular atrophy.

Applications with the US Food and Drug Administration and European Medicines Agency are expected in Q1 2025, and a US launch in Q4.

Scholar Rock ( SRRK ) also plans to focus on three key priorities in 2025, including commercialization, expanded use of apitegromab, and advancing anti-myostatin program for cardiometabolic disorders.

Key milestones for the company include starting the phase 2 trial in SMA patients under two years old by mid-2025, phase 2 obesity trial data in Q2, and filing an investigational new drug application for SRK-439 to treat obesity in Q3, Scholar Rock ( SRRK ) said.

Scholar Rock ( SRRK ) said its current cash and equivalent funds are enough to cover operation through Q4 2026.